GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » Price-to-Owner-Earnings

Genix Pharmaceuticals (TSXV:GENX) Price-to-Owner-Earnings : (As of May. 28, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals Price-to-Owner-Earnings?

As of today (2025-05-28), Genix Pharmaceuticals's share price is C$0.03. Genix Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Genix Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Genix Pharmaceuticals was 80.00. The lowest was 10.00. And the median was 40.00.


TSXV:GENX's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.945
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-28), Genix Pharmaceuticals's share price is C$0.03. Genix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was C$0.00. Therefore, Genix Pharmaceuticals's PE Ratio (TTM) for today is 30.00.

As of today (2025-05-28), Genix Pharmaceuticals's share price is C$0.03. Genix Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was C$-0.00. Therefore, Genix Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Genix Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Genix Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals Price-to-Owner-Earnings Chart

Genix Pharmaceuticals Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genix Pharmaceuticals Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genix Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genix Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's Price-to-Owner-Earnings falls into.


;
;

Genix Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genix Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.03/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genix Pharmaceuticals  (TSXV:GENX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genix Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genix Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genix Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically, the company operates only in Canada.
Executives
Sina Pirooz Director
Paul Chow 10% Security Holder, Director
Jamie A. Lewin Director

Genix Pharmaceuticals Headlines

No Headlines